JP2024504136A - 「新規な二環式ペプチド」 - Google Patents

「新規な二環式ペプチド」 Download PDF

Info

Publication number
JP2024504136A
JP2024504136A JP2023543460A JP2023543460A JP2024504136A JP 2024504136 A JP2024504136 A JP 2024504136A JP 2023543460 A JP2023543460 A JP 2023543460A JP 2023543460 A JP2023543460 A JP 2023543460A JP 2024504136 A JP2024504136 A JP 2024504136A
Authority
JP
Japan
Prior art keywords
amino acid
bicyclic
alanine
peptidomimetic
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023543460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504136A5 (enExample
Inventor
ラオ スダー
Original Assignee
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021900114A external-priority patent/AU2021900114A0/en
Application filed by ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ filed Critical ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Publication of JP2024504136A publication Critical patent/JP2024504136A/ja
Publication of JP2024504136A5 publication Critical patent/JP2024504136A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023543460A 2021-01-19 2022-01-19 「新規な二環式ペプチド」 Pending JP2024504136A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021900114 2021-01-19
AU2021900114A AU2021900114A0 (en) 2021-01-19 Novel bicyclic peptipes
PCT/AU2022/050023 WO2022155704A1 (en) 2021-01-19 2022-01-19 Novel bicyclic peptides

Publications (2)

Publication Number Publication Date
JP2024504136A true JP2024504136A (ja) 2024-01-30
JP2024504136A5 JP2024504136A5 (enExample) 2025-01-27

Family

ID=82548163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543460A Pending JP2024504136A (ja) 2021-01-19 2022-01-19 「新規な二環式ペプチド」

Country Status (9)

Country Link
US (1) US20240117005A1 (enExample)
EP (1) EP4281486A4 (enExample)
JP (1) JP2024504136A (enExample)
KR (1) KR20230146025A (enExample)
CN (1) CN117062842A (enExample)
AU (1) AU2022209878A1 (enExample)
CA (1) CA3208598A1 (enExample)
IL (1) IL304545A (enExample)
WO (1) WO2022155704A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023307414A1 (en) * 2022-07-13 2025-02-27 The Council Of The Queensland Institute Of Medical Research Novel inhibitors of histone methyltransferase nuclear localisation
CN121108243A (zh) * 2025-01-03 2025-12-12 中国药科大学 一种非核糖体多肽化合物及其合成基因簇bnp37和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077062A2 (en) * 2003-02-27 2004-09-10 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP2018537965A (ja) * 2015-10-30 2018-12-27 アフィボディ・アーベー Ｐｄ−ｌ１に対して親和性を有する新規ポリペプチド
WO2019136531A1 (en) * 2018-01-15 2019-07-18 University Of Canberra Proteinaceous molecules and uses therefor
JP2019189591A (ja) * 2018-04-27 2019-10-31 日東電工株式会社 ヒトｐｄ−ｌ１結合性ペプチド
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
WO2020128527A1 (en) * 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2767730T3 (es) * 2015-04-30 2020-06-18 Univ Kyoto Método para predecir el efecto terapéutico del inhibidor PD-1/PD-L1 usando una anomalía en PD-L1(CD274) como índice

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077062A2 (en) * 2003-02-27 2004-09-10 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP2018537965A (ja) * 2015-10-30 2018-12-27 アフィボディ・アーベー Ｐｄ−ｌ１に対して親和性を有する新規ポリペプチド
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
WO2019136531A1 (en) * 2018-01-15 2019-07-18 University Of Canberra Proteinaceous molecules and uses therefor
JP2019189591A (ja) * 2018-04-27 2019-10-31 日東電工株式会社 ヒトｐｄ−ｌ１結合性ペプチド
WO2020128527A1 (en) * 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DU W ET AL.: "KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation", CELL DEATH & DIFFERENTIATION, vol. 28, no. 4, JPN6025050831, 2 November 2020 (2020-11-02), pages 1284 - 1300, ISSN: 0005754003 *
SATELLI A ET AL.: "Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells", SCIENTIFC REPORTS, vol. vol.6, 28910, JPN6025050832, 1 July 2016 (2016-07-01), ISSN: 0005754004 *

Also Published As

Publication number Publication date
IL304545A (en) 2023-09-01
US20240117005A1 (en) 2024-04-11
KR20230146025A (ko) 2023-10-18
WO2022155704A1 (en) 2022-07-28
AU2022209878A1 (en) 2023-09-07
CN117062842A (zh) 2023-11-14
EP4281486A4 (en) 2025-01-08
EP4281486A1 (en) 2023-11-29
CA3208598A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
US11999779B2 (en) Anti-complement factor C1q Fab fragments and uses thereof
US7071300B2 (en) IGF antagonist peptides
EP3054973B1 (en) Tm4sf1 binding proteins and methods of using same
CN102137680A (zh) 用apoe肽治疗癌症的方法
US20190092822A1 (en) BH4 Stabilized Peptides And Uses Thereof
AU2019207534A1 (en) Proteinaceous molecules and uses therefor
US20110224133A1 (en) Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases
US20240117005A1 (en) Novel bicyclic peptides
US20130316958A1 (en) Highly potent peptides to control cancer and neurodegenerative diseases
JP5475406B2 (ja) Ｇｂｓ毒素受容体
WO2001088191A1 (en) A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿
JP7303189B2 (ja) 網膜色素変性症治療用ペプチド
JP2025527370A (ja) ヒストンメチルトランスフェラーゼ核局在化の新規阻害剤
AU2018363880B2 (en) Immunogenic compositions and uses therefor
WO2023077188A1 (en) Proteinaceous molecules and uses therefor
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof
US7589185B2 (en) Nucleotide sequences and protein(s) encoded by such nucleotides for modulation of apoptosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260616